We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

101 hedge funds and large institutions have $428M invested in Vanda Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 34

8% less funds holding

Funds holding: 110 → 101 (-9)

23% less call options, than puts

Call options by funds: $10.5M | Put options by funds: $13.7M

31% less capital invested

Capital invested by funds: $622M → $428M (-$195M)

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
101
Holders Change
-9
Holders Change %
-8.18%
% of All Funds
2.93%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
7
Increased
38
Reduced
34
Closed
16
Calls
$10.5M
Puts
$13.7M
Net Calls
-$3.14M
Net Calls Change
-$36.4M

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$14.2M
2
JGC
J. Goldman & Co
New York
+$11.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$8.88M
4
Millennium Management
Millennium Management
New York
+$4.71M
5
State Street
State Street
Massachusetts
+$3.41M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$7.36M
2
CCM
Cupps Capital Management
Illinois
-$2.01M
3
Invesco
Invesco
Georgia
-$1.67M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.55M
5
SCA
Signpost Capital Advisors
New York
-$1.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
26
Hudson Bay Capital Management
Connecticut
$2.1M – – –
Principal Financial Group
27
Principal Financial Group
Iowa
$2.04M -$46.4K -3,540 -2%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$2.01M +$29.5K +2,248 +1%
Deutsche Bank
29
Deutsche Bank
Germany
$1.91M +$721K +55,011 +43%
Alyeska Investment Group
30
Alyeska Investment Group
Illinois
$1.79M +$1.61M +122,695 +248%
GC
31
Guggenheim Capital
Illinois
$1.52M +$223K +17,039 +13%
Macquarie Group
32
Macquarie Group
Australia
$1.35M -$655K -50,000 -28%
QBFM
33
QS Batterymarch Financial Management
New York
$1.26M -$1.28M -97,467 -45%
TD Asset Management
34
TD Asset Management
Ontario, Canada
$1.24M +$43.3K +3,300 +3%
Wellington Management Group
35
Wellington Management Group
Massachusetts
$1.13M -$227K -17,300 -14%
SGAM
36
Smith Group Asset Management
Texas
$1.09M -$4.59K -350 -0.3%
BIM
37
BlackRock Investment Management
Delaware
$1.03M +$13K +989 +1%
GGHC
38
Gilder Gagnon Howe & Co
New York
$864K +$1.09M +83,190 New
BCM
39
Bridgeway Capital Management
Texas
$830K – – –
GS
40
Gagnon Securities
New York
$774K -$234K -17,826 -19%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$765K -$98.3K -7,500 -9%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$704K -$269K -20,532 -23%
WMSA
43
Weiss Multi-Strategy Advisers
New York
$675K -$131K -10,000 -13%
SO
44
STRS Ohio
Ohio
$670K +$535K +40,800 +172%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$650K +$9.9K +755 +1%
Charles Schwab
46
Charles Schwab
California
$636K +$183K +13,953 +29%
Ameriprise
47
Ameriprise
Minnesota
$630K +$790K +60,295 +17,227%
TA
48
Teachers Advisors
New York
$599K – – –
AllianceBernstein
49
AllianceBernstein
Tennessee
$576K – – –
IHM
50
Iguana Healthcare Management
New York
$519K -$655K -50,000 -50%
1
2
3 4 5

VNDA Hedge Fund Activity: Q3 2014 in Review

101 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2014, worth a combined $428M — down 31% from $622M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of VNDA and 7 opened new positions — a net loss of 9 holders — while 34 trimmed existing stakes and 38 added.

The largest buyer was Deerfield Management, adding an estimated $14.2M. The largest seller was OrbiMed, exiting entirely with an estimated $7.36M sold.

  • 101 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2014, down from 110 in Q2 2014.
  • Funds reported $428M of Vanda Pharmaceuticals stock for Q3 2014, down 31% quarter-over-quarter.
  • 7 funds opened new Vanda Pharmaceuticals positions in Q3 2014 and 16 closed out, a net change of -9 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2014 was Deerfield Management, an estimated $14.2M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2014 was OrbiMed, an estimated $7.36M sold.

Based on aggregated 13F filings for Q3 2014.